Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Roche joining forces to forward precision oncology

Published: 11 Dec 2017

Views: 2210

Rating:

Save

Ian Walker - Roche Foundation Medicine, Basel, Switzerland

Ian Walker talks to ecancer at EAPM 2017 in Belfast.

He spoke about precision oncology and how joining forces with other pharmaceutical companies will greatly aid patients in Europe.

This is important because metastatic cancers are so diverse, so a lot of data is needed.

Related Videos

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus

Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale...

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus ( Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale Tomasini )

Multiple myeloma in a resource constrained setting

Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda

Multiple myeloma in a resource constrained setting ( Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda )

Relapsed Refractory Multiple Myeloma

Dr Hari Menon - St. Johns National Academy of Health Sciences, Bengaluru, India

$Relapsed Refractory Multiple Myeloma ( Dr Hari Menon - St. Johns National Academy of Health Sciences, Bengaluru, India )$

OncoAlert Round Up for September 15-21, 2023

Dr Gil Morgan - Executive Director, OncoAlert

OncoAlert Round Up for September 15-21, 2023 ( Dr Gil Morgan - Executive Director, OncoAlert )

Choosing Wisely in pathology

Dr Angela Mlole - Ocean Road Cancer Institute, Dar es Salaam, Tanzania

Choosing Wisely in pathology ( Dr Angela Mlole - Ocean Road Cancer Institute, Dar es Salaam, Tanzania )

Choosing Wisely in radiology Tanzania

Dr Revelian Iramu - Ocean Road Cancer Institute, Dar es Salaam, Tanzania

Choosing Wisely in radiology Tanzania ( Dr Revelian Iramu - Ocean Road Cancer Institute, Dar es Salaam, Tanzania )

Combination of camonsertib plus PARPi shows clinical activity in DDR-aberrant...

Dr Timothy Yap - The University of Texas MD Anderson Cancer Center, Houston, USA

Combination of camonsertib plus PARPi shows clinical activity in DDR-aberrant tumours ( Dr Timothy Yap - The University of Texas MD Anderson Cancer Center, Houston, USA )

SOFT study: Clinical relevance of genomic alterations in premenopausal HR+...

Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia

SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer ( Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia )

The placebo effect in oncology trials and the criteria for approving drugs

Dr Bishal Gyawali - Queen's University, Kingston, Canada

The placebo effect in oncology trials and the criteria for approving drugs ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )

More from ecancer